AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8723472 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg), Trimethoprim (200 mg), Dapsone (100 mg)
Number of subjects: 8
Study 1328362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose angiotensin II infusion
Number of subjects: 24
Study 1328362 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 2865712 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dipipanone
Number of subjects: 12
Study 2865712 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dipipanone
Number of subjects: 12
Study 2865712 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dipipanone
Number of subjects: 12
Study 3312977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (0.5 mL, 1 mg/mL)
Number of subjects: 37
Study 3312977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL)
Number of subjects: 37
Study 31736068 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04‐HPV‐16/18 vaccine (in Arms A and B)
Number of subjects: 4871
Study 31736068 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (in Arms A/B and all Arm C)
Number of subjects: 4871
Study 30319010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement filling in the right hind femur
Number of subjects: 0
Study 30319010 — intervention group
Group type: COMPARATOR
Intervention: Control leg (non-cemented contralateral leg)
Number of subjects: 0
Study 26582910 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration plus PCI
Number of subjects: 440
Study 26582910 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 440
Study 26333743 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic arthroscopic simulation tasks using a box model
Number of subjects: 49
Study 26333743 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater and intra-rater reliability assessment
Number of subjects: 49
Study 24097234 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal glove and gown use
Number of subjects: 26180
Study 24097234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 26180
Study 21496417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive with moderate and severe OSA group
Number of subjects: 184
Study 18347489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-absorbing catgut suture
Number of subjects: 47
Study 18347489 — intervention group
Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 47
Study 16837676 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 10101
Study 12667722 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual 4mg
Number of subjects: 16
Study 12667722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11082801 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week nurse-managed, peer-led smoking cessation intervention including 21 mg nicotine patch therapy for 6 weeks, weekly counseling, and skills training
Number of subjects: 8
Study 11082801 — intervention group
Group type: COMPARATOR
Intervention: Control group received written self-help materials for smoking cessation
Number of subjects: 8
Study 11082801 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week nurse-managed, peer-led smoking cessation intervention
Number of subjects: 8
Study 8833712 — intervention group
Group type: EXPERIMENTAL
Intervention: FULL wet suit
Number of subjects: 5
Study 8833712 — intervention group
Group type: EXPERIMENTAL
Intervention: LONG wet suit
Number of subjects: 5
Study 8833712 — intervention group
Group type: EXPERIMENTAL
Intervention: SHORT wet suit
Number of subjects: 5
Study 8833712 — intervention group
Group type: COMPARATOR
Intervention: Conventional swimming suit (SS)
Number of subjects: 5
Study 1442591 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-wave thrombus ablation (1,000 shocks/24 kv)
Number of subjects: 15
Study 1442591 — intervention group
Group type: COMPARATOR
Intervention: Control (no shock waves)
Number of subjects: 15
Study 2931153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 0
Study 2931153 — intervention group
Group type: COMPARATOR
Intervention: Early mobilisation
Number of subjects: 0
Study 29680812 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application used weekly for 12 months
Number of subjects: 60
Study 29680812 — intervention group
Group type: COMPARATOR
Intervention: Usual care involving regular (approximately 3 monthly) CF outpatient clinic appointments
Number of subjects: 60
Study 30634207 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Shengji Recipe (JSR), one dose per day for 8 weeks
Number of subjects: 86
Study 30634207 — intervention group
Group type: COMPARATOR
Intervention: Control group: mixture of dexamethasone, lidocaine, and gentamicin, 10 mL each time before radiation
Number of subjects: 86
Study 23519913 — intervention group
Group type: COMPARATOR
Intervention: Acidulated phosphate fluoride (APF) gel for 4 min
Number of subjects: 60
Study 23519913 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser applied before APF gel (10 mJ, 200 Hz, 10 s)
Number of subjects: 60
Study 23519913 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser applied through APF gel (10 mJ, 200 Hz, 10 s)
Number of subjects: 60
Study 23519913 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study 22372591 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg every second day
Number of subjects: 60
Study 22372591 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg daily
Number of subjects: 60
Study 22372591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of testosterone undecanoate and estradiol valerate
Number of subjects: 60
Study 22372591 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 20451681 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg/day subcutaneously for 14 days
Number of subjects: 10
Study 20451681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20451681 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 10
Study 17953787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Children intervention (FV curriculum and improved FV availability)
Number of subjects: 1472
Study 15943872 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep inspiration (DI) induced bronchodilation after constricting the airways with methacholine
Number of subjects: 15
Study 12477078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetindene (H1‐receptor antagonist) plus cimetidine (H2‐receptor antagonist)
Number of subjects: 17
Study 12477078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12477078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetindene plus cimetidine
Number of subjects: 17
Study 10740330 — intervention group
Group type: EXPERIMENTAL
Intervention: goserelin
Number of subjects: 160
Study 10740330 — intervention group
Group type: COMPARATOR
Intervention: danazol
Number of subjects: 160
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent doxorubicin
Number of subjects: 0
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent paclitaxel
Number of subjects: 0
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and paclitaxel
Number of subjects: 0
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen used by Gianni et al
Number of subjects: 0
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of dexrazoxane
Number of subjects: 0
Study 8893901 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin combined with paclitaxel
Number of subjects: 0
Study 8893901 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel
Number of subjects: 0
Study 1575171 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg dose)
Number of subjects: 0
Study 1575171 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 2859819 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac
Number of subjects: 592
Study 2859819 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 592
Study 2859819 — intervention group
Group type: COMPARATOR
Intervention: No gastric emptying procedures
Number of subjects: 592
Study 31536118 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-for-gestational-age infants
Number of subjects: 316
Study 31536118 — intervention group
Group type: COMPARATOR
Intervention: Appropriate-for-gestational-age infants
Number of subjects: 316
Study 31536118 — intervention group
Group type: COMPARATOR
Intervention: Positive-pressure ventilation
Number of subjects: 316
Study 31536118 — intervention group
Group type: COMPARATOR
Intervention: Patent ductus arteriosus (PDA)
Number of subjects: 316
Study 31536118 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient/energy intakes
Number of subjects: 316
Study 29235076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic/resistance and cognitive dual task (n=28)
Number of subjects: 90
Study 29235076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic/resistance and computer lessons (n=21)
Number of subjects: 90
Study 29235076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises and cognitive dual task (n=23)
Number of subjects: 90
Study 29235076 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises and computer lessons (n=18)
Number of subjects: 90
Study 27005470 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific movement control exercise (SMCE) combined with manual therapy
Number of subjects: 70
Study 27005470 — intervention group
Group type: COMPARATOR
Intervention: General exercise combined with manual therapy
Number of subjects: 70
Study 25721344 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Eye Training (QET)
Number of subjects: 30
Study 25721344 — intervention group
Group type: COMPARATOR
Intervention: Traditional Training (TT)
Number of subjects: 30
Study 23769990 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU/TBI
Number of subjects: 85
Study 23769990 — intervention group
Group type: COMPARATOR
Intervention: TBI
Number of subjects: 85
Study 20496059 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational practice
Number of subjects: 36
Study 20496059 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 36
Study 20496059 — intervention group
Group type: COMPARATOR
Intervention: No practice (Control)
Number of subjects: 36
Study 18293016 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐hydroxyl beta‐methyl butyrate, glutamine, and arginine (HMB/Arg/Gln)
Number of subjects: 472
Study 18293016 — intervention group
Group type: COMPARATOR
Intervention: isonitrogenous, isocaloric control mixture
Number of subjects: 472
Study 15733808 — intervention group
Group type: EXPERIMENTAL
Intervention: BFI‐K (Korean version of the Brief Fatigue Inventory)
Number of subjects: 178
Study 15733808 — intervention group
Group type: EXPERIMENTAL
Intervention: BFI‐K
Number of subjects: 178
Study 13680197 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FEF
Number of subjects: 5
Study 13680197 — intervention group
Group type: COMPARATOR
Intervention: Displacement injection of 0.01 mg/kg of unlabelled flumazenil
Number of subjects: 5
Study 10608469 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (220 mmol/day)
Number of subjects: 163
Study 10608469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (20 mmol/day)
Number of subjects: 163
Study 7723358 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 2.5 mg twice daily
Number of subjects: 10
Study 7723358 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg daily
Number of subjects: 10
Study 7723358 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 7723358 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine and atenolol (comparison)
Number of subjects: 10
Study 2201496 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 18
Study 2201496 — intervention group
Group type: EXPERIMENTAL
Intervention: HSH 6075 (14% sorbitol/78% hydrogenated maltooligosaccharides)
Number of subjects: 18
Study 2201496 — intervention group
Group type: EXPERIMENTAL
Intervention: HSH 5875 (7% sorbitol/60% maltitol)
Number of subjects: 18
Study 2201496 — intervention group
Group type: COMPARATOR
Intervention: C-peptide response
Number of subjects: 18
Study 2201496 — intervention group
Group type: COMPARATOR
Intervention: Breath H2 after glucose
Number of subjects: 18
Study 2201496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distress
Number of subjects: 18
Study 7273647 — intervention group
Group type: EXPERIMENTAL
Intervention: TNI
Number of subjects: 0
Study 7273647 — intervention group
Group type: EXPERIMENTAL
Intervention: TNI followed by LOPP
Number of subjects: 0
Study 7273647 — intervention group
Group type: EXPERIMENTAL
Intervention: TNI for patients without splenic involvement
Number of subjects: 0
Study 7273647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (randomised between MOPP and LOPP) for patients with splenic involvement
Number of subjects: 0
Study 7273647 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 0
Study 7273647 — intervention group
Group type: COMPARATOR
Intervention: LOPP
Number of subjects: 0
Study 31935382 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch with newly sourced adhesive component (test)
Number of subjects: 70
Study 31935382 — intervention group
Group type: COMPARATOR
Intervention: EVRA patch (reference)
Number of subjects: 70
Study 30573280 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting (DS)
Number of subjects: 342
Study 30573280 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting (CS)
Number of subjects: 342
Study 28600161 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Problem‐Solving (HELPS) intervention consisting of six group sessions conducted approximately monthly interspersed with individualized coaching calls.
Number of subjects: 400
Study 28600161 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 400
Study 25112845 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sulodexide daily for 12 months
Number of subjects: 130
Study 25112845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching dose) daily for 12 months
Number of subjects: 130
Study 24028441 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 30
Study 24028441 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 30
Study 21413691 — intervention group
Group type: COMPARATOR
Intervention: Standardized curcuminoid mixture
Number of subjects: 0
Study 21413691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin formulation (Meriva)
Number of subjects: 0
Study 19109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon juice
Number of subjects: 90
Study 19109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon grass (Cymbopogon citratus)
Number of subjects: 90
Study 19109001 — intervention group
Group type: COMPARATOR
Intervention: Gentian violet aqueous solution 0.5%
Number of subjects: 90
Study 17683329 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 95
Study 17683329 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-gauge needle
Number of subjects: 95
Study 15074737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ralstron applicator
Number of subjects: 50
Study 15074737 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Rotterdam applicator
Number of subjects: 50
Study 15074737 — intervention group
Group type: COMPARATOR
Intervention: Both applicators
Number of subjects: 50
Study 11506055 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g AG per day
Number of subjects: 20
Study 11506055 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g AG per day
Number of subjects: 20
Study 11506055 — intervention group
Group type: EXPERIMENTAL
Intervention: AG (15 g and 30 g)
Number of subjects: 20
Study 11506055 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 20
Study 9760014 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate inhaled by Rotahaler (Becotide Rotacaps)
Number of subjects: 182
Study 9760014 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate inhaled by Cyclohaler (Beclomethasone Cyclocaps)
Number of subjects: 182
Study 9760014 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication use in Rotahaler group
Number of subjects: 182
Study 9760014 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from study
Number of subjects: 182
Study 8583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy (7.5 or 15 mg once daily)
Number of subjects: 172
Study 8583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril combined with hydrochlorothiazide (7.5 or 15 mg daily with 25 mg hydrochlorothiazide)
Number of subjects: 172
Study 8583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy or combination therapy
Number of subjects: 172
Study 2515971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine administration
Number of subjects: 24
Study 2515971 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 24
Study 2515971 — intervention group
Group type: COMPARATOR
Intervention: Diabetics with neuropathy
Number of subjects: 24
Study 2515971 — intervention group
Group type: COMPARATOR
Intervention: Diabetics without neuropathy
Number of subjects: 24
Study 2515971 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study 872912 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary rules
Number of subjects: 48
Study 872912 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical rules
Number of subjects: 48
Study 29419533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 8 weeks then once monthly for 4 months
Number of subjects: 30
Study 29419533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29419533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU
Number of subjects: 30
Study 28116776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 461
Study 28116776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 461
Study 26147153 — intervention group
Group type: EXPERIMENTAL
Intervention: HBX (HYBENX® Oral Tissue Decontaminant™) in association with sub‐gingival ultrasonic debridement (UD)
Number of subjects: 16
Study 26147153 — intervention group
Group type: EXPERIMENTAL
Intervention: HBX (HYBENX® Oral Tissue Decontaminant™) as monotherapy
Number of subjects: 16
Study 26147153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HBX-UD treatment
Number of subjects: 16
Study 26147153 — intervention group
Group type: COMPARATOR
Intervention: Control group (UD only)
Number of subjects: 16
Study 26182818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 60
Study 26182818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 22449144 — intervention group
Group type: EXPERIMENTAL
Intervention: SINA group (step 1 for ACT scores >= 20, step 2 for scores 16-19, step 3 for scores < 16)
Number of subjects: 90
Study 22449144 — intervention group
Group type: COMPARATOR
Intervention: GINA group (step 2 for persistent asthma symptoms, step 3 for severely uncontrolled disease)
Number of subjects: 90
Study 22449144 — intervention group
Group type: EXPERIMENTAL
Intervention: SINA group
Number of subjects: 90
Study 22449144 — intervention group
Group type: COMPARATOR
Intervention: GINA group
Number of subjects: 90
Study 19325200 — intervention group
Group type: EXPERIMENTAL
Intervention: RaCe Rotary Instruments
Number of subjects: 84
Study 19325200 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexMaster Rotary Instruments
Number of subjects: 84
Study 19325200 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile Rotary Instruments
Number of subjects: 84
Study 17328819 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic group (400 mg garlic, 1 mg allicin, twice daily)
Number of subjects: 150
Study 17328819 — intervention group
Group type: EXPERIMENTAL
Intervention: Anethum group (650 mg, twice daily)
Number of subjects: 150
Study 17328819 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 150
Study 15167450 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (an inhibitor of angiotensin II type 1 (AT1) receptors)
Number of subjects: 40
Study 15167450 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 40
Study 15167450 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 40
Study 11293555 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 718
Study 11293555 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg QD
Number of subjects: 718
Study 11293555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 9658786 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 60
Study 9658786 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 60
Study 7972803 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection into the splenic artery (n=34)
Number of subjects: 71
Study 7972803 — intervention group
Group type: COMPARATOR
Intervention: Injection into the superior mesenteric artery (SMA) (n=37)
Number of subjects: 71
Study 2757903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 254
Study 31692613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by Misoprostol (Group M, n=60)
Number of subjects: 120
Study 31692613 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone followed by Ethacridine Lactate and Oxytocin (Group E, n=60)
Number of subjects: 120
Study 27942720 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide
Number of subjects: 549